MAZZAFERRO, VINCENZO MARIA
MAZZAFERRO, VINCENZO MARIA
Dipartimento di Oncologia ed Emato-Oncologia
A prospective randomized, open-labeled; trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma
2010-05-11 A. Schnitzbauer, C. Zuelke, C. Graeb, J. Rochon, I. Bilbao, P. Burra, K.P. De Jong, C. Duvoux, N.M. Kneteman, R. Adam, W.O. Bechstein, T. Becker, S. Beckebaum, O. Chazouilleres, U. Cillo, M. Colledan, F. Fandrich, J. Gugenheim, J.P. Hauss, M. Heise, E. Hidalgo, N. Jamieson, A. Konigsrainer, P.E. Lamby, J.P. Lerut, H. Makisalo, R. Margreiter, V. Mazzaferro, I. Mutzbauer, G. Otto, G.P. Pageaux, A.D. Pinna, J. Pirenne, M. Rizell, G.E. Rossi, L. Rostaing, A. Roy, V. Sanchez Turrion, J. Schimdt, R. Troisi, B. Van Hoek, U. Valente, P. Wolf, H. Wolters, D.F. Mirza, T. Scholz, R. Steininger, G. Soderdahl, S.L. Strasser, K.W. Jauch, P. Neuhaus, H.J. Schlitt, E.K. Geissler
Activity and safety of RAD001 (everolimus) in patients affected by biliary tract cancer progressing after prior chemotherapy : a phase II ITMO study
2014-08-01 R. Buzzoni, S. Pusceddu, E. Bajetta, F. De Braud, M. Platania, C. Iannacone, M. Cantore, A. Mambrini, A. Bertolini, O. Alabiso, A. Ciarlo, C. Turco, V. Mazzaferro
Adjuvant radiotherapy in urothelial neuroendocrine carcinoma
2020-06-01 R.E. Rossi, M. Monteleone, M. Altomare, L. Cattaneo, M. Torchio, J. Coppa, V. Mazzaferro
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM) : a phase 3, randomised, double-blind, placebo-controlled trial
2015-10-01 J. Bruix, T. Takayama, V. Mazzaferro, G.Y. Chau, J. Yang, M. Kudo, J. Cai, R.T Poon, K.H. Han, W. Young Tak, H. Chu Lee, T. Song, S. Roayaie, L. Bolondi, K. Sik Lee, M. Makuuchi, F. Souza, M.-Aude Le Berre, G. Meinhardt, J.M. Llovet
Alpha-Fetoprotein (AFP) in liver transplantation for HCC: The lower, the better
2018-08-01 V. Mazzaferro, M. Droz Dit Busset, S. Bhoori
Amino acid kinetics during the anhepatic phase of liver transplantation
2002-06-01 A. Battezzati, A. Caumo, A. Fattorini, L.P. Sereni, J.C. Coppa, R. Romito, M. Ammatuna, E. Regalia, V. Mazzaferro, L. Luzi
Antitumor Activity of a Novel Fibroblast Growth Factor Receptor Inhibitor for Intrahepatic Cholangiocarcinoma
2019-10-01 C. Raggi, K. Fiaccadori, M. Pastore, M. Correnti, B. Piombanti, E. Forti, N. Navari, G. Abbadessa, T. Hall, A. Destro, L. Di Tommaso, M. Roncalli, F. Meng, S. Glaser, E. Rovida, C. Peraldo-Neia, P. Olaizola, J.M. Banales, A. Gerussi, A. Elvevi, M. Droz Dit Busset, S. Bhoori, V. Mazzaferro, G. Alpini, F. Marra, P. Invernizzi
Approach to hepatic metastases from colorectal adenocarcinoma
1988-01-01 V. Mazzaferro, V.J. Dindzans, L. Makowka, D.H. Van Thiel
Approccio chirurgico alle metastasi epatiche da neoplasie neuroendocrine dell'apparato digerente: resezione o trapianto?
2007-01-01 V. Mazzaferro, A. Pulvirenti, J. Coppa, M. Schiavo, E. Regalia, T. Camerini, T. Collini
ARQ 087, an oral pan- fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced and/or metastatic intrahepatic cholangiocarcinoma (iCCA)
2016-06-01 V.M. Mazzaferro, W. Shaib, L. Rimassa, W. Harris, N. Personeni, B. El-rayes, A. Tolcher, T. Hall, Y. Wang, B. Schwartz, J. Kazakin, M. DROZ DIT BUSSET, C. Cotsoglou, K. Papadopoulos
ASO Author Reflections: Amid Anatomic Restrictions, Three-Dimensional Surgical Planning Eases En Bloc Resection of the Retro-Hepatic Vena Cava and the Caudate Lobe of the Liver
2021-01-01 M. Altomare, V. Mazzaferro
ASO Author Reflections: Less is more: Organ-Sparing Approach for the Surgical Treatment of Gastric Adenocarcinoma
2022-03-01 M. Maspero, C. Sposito, V. Mazzaferro
ASO Visual Abstract: Impact of Surgical Margins on Overall Survival After Gastrectomy for Gastric Cancer: A Validation of Japanese Gastric Cancer Association Guidelines on a Western Series
2022-01-01 M. Maspero, C. Sposito, A. Benedetti, M. Virdis, M. Di Bartolomeo, M. Milione, V. Mazzaferro
Assessing Competing Risks for Death Following Liver Transplantation for Hepatocellular Carcinoma
2019-04-01 C. Sposito, A. Cucchetti, V. Mazzaferro
Assessment of insulin sensitivity based on a fasting blood sample in men with liver cirrhosis before and after liver transplantation
2003-08-27 G. Perseghin, A. Caumo, V. Mazzaferro, A. Pulvirenti, L. Piceni Sereni, R. Romito, G. Lattuada, J.C. Coppa, F. Costantino, E. Regalia, L. Luzi
Association between HLA class I and class II alleles and HCV, HBV infection in patients with hepatocellular carcinoma
2001-01-01 C. Lombardo, A. Mazzocchi, A. Tagger, M.L. Ribero, D. Settesoldi, J. Coppa, F. Arienti, P. Notti, V. Mazzaferro, F. Ravagnani
Authors' response to the letter : Liver resection for patients with hepatocellular carcinoma and macrovascular invasion, multiple tumours or portal hypertension by Zhong et al
2015-03-01 J. Bruix, G. Gores, V. Mazzaferro
Average treatment effect of hepatic resection versus locoregional therapies for hepatocellular carcinoma
2017-11-01 A. Cucchetti, V. Mazzaferro, A. Pinna, C. Sposito, R. Golfieri, C. Serra, C. Spreafico, F. Piscaglia, A. Cappelli, M. Bongini, M. Cucchi, M. Cescon
Balancing donor and recipient risk factors in liver transplantation : the value of D-MELD with particular reference to HCV recipients
2011-01-01 A.W. Avolio, U. Cillo, M. Salizzoni, L. De Carlis, M. Colledan, G.E. Gerunda, V. Mazzaferro, G. Tisone, R. Romagnoli, L. Caccamo, M. Rossi, A. Vitale, A. Cucchetti, L. Lupo, S. Gruttadauria, N. Nicolotti, P. Burra, A. Gasbarrini, S. Agnes
Basi scientifiche per la definizione di linee-guida in ambito clinico per i tumori neuroendocrini del tratto Gastro-Entero-Pancreatico (GEP)
2009-01-01 C. Capella, L. Catena, A. Chiti, F. Cirillo, A. Colao, C. De Angelis, M. Ducceschi, A. Marchianò, A. Martinetti, V. Mazzaferro, G. Paganelli, M. Platania, E. Seregni, C. Spreafico